HTG Molecular Diagnostics Inc (NASDAQ:HTGM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

According to Zacks, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. “

Several other equities research analysts have also commented on the stock. Rodman & Renshaw boosted their target price on shares of HTG Molecular Diagnostics from $4.50 to $6.00 and gave the stock a “buy” rating in a research report on Tuesday. Canaccord Genuity boosted their target price on shares of HTG Molecular Diagnostics from $5.50 to $6.50 and gave the stock a “hold” rating in a research report on Wednesday, April 19th.

HTG Molecular Diagnostics (NASDAQ:HTGM) traded down 4.09% during trading on Tuesday, hitting $3.99. 808,735 shares of the company traded hands. HTG Molecular Diagnostics has a 52-week low of $1.20 and a 52-week high of $13.25. The firm’s market cap is $32.13 million. The company’s 50-day moving average is $5.55 and its 200 day moving average is $3.04.

HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its earnings results on Monday, May 15th. The medical research company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.15. The company had revenue of $1.37 million for the quarter, compared to analysts’ expectations of $2.44 million. HTG Molecular Diagnostics had a negative return on equity of 356.46% and a negative net margin of 532.94%. On average, equities analysts anticipate that HTG Molecular Diagnostics will post ($2.28) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “HTG Molecular Diagnostics Inc (HTGM) Downgraded by Zacks Investment Research to Hold” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/05/16/htg-molecular-diagnostics-inc-htgm-downgraded-by-zacks-investment-research-to-hold.html.

In other HTG Molecular Diagnostics news, insider Plc Glaxosmithkline sold 300,000 shares of the business’s stock in a transaction on Monday, March 27th. The shares were sold at an average price of $10.15, for a total transaction of $3,045,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 8.10% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of HTGM. Granahan Investment Management Inc. MA bought a new stake in shares of HTG Molecular Diagnostics during the first quarter valued at approximately $228,000. Two Sigma Securities LLC bought a new stake in shares of HTG Molecular Diagnostics during the first quarter valued at approximately $150,000. UBS Group AG bought a new stake in shares of HTG Molecular Diagnostics during the first quarter valued at approximately $137,000. Vanguard Group Inc. raised its stake in shares of HTG Molecular Diagnostics by 35.7% in the first quarter. Vanguard Group Inc. now owns 97,393 shares of the medical research company’s stock valued at $674,000 after buying an additional 25,635 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of HTG Molecular Diagnostics by 32.3% in the fourth quarter. Renaissance Technologies LLC now owns 58,200 shares of the medical research company’s stock valued at $130,000 after buying an additional 14,206 shares during the last quarter. Institutional investors own 47.31% of the company’s stock.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

5 Day Chart for NASDAQ:HTGM

Get a free copy of the Zacks research report on HTG Molecular Diagnostics (HTGM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for HTG Molecular Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc and related companies with MarketBeat.com's FREE daily email newsletter.